Magnesium isoglycyrrhizinate has hepatoprotective effects in an oxaliplatin‑induced model of liver injury

Zou,Xueqing; Wang,Yongmei; Peng,Cheng; Wang,Ben; Niu,Zhengchuan; Li,Zequn; Niu,Jun

doi:10.3892/ijmm.2018.3787

Magnesium isoglycyrrhizinate has hepatoprotective effects in an oxaliplatin‑induced model of liver injury

Authors:
- Xueqing Zou
- Yongmei Wang
- Cheng Peng
- Ben Wang
- Zhengchuan Niu
- Zequn Li
- Jun Niu
View Affiliations

Affiliations: Department of General Surgery, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China, Center of Diagnosis and Treatment of Breast Disease, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China
Published online on: July 19, 2018 https://doi.org/10.3892/ijmm.2018.3787
Pages: 2020-2030
Copyright: © Zou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oxaliplatin is a core chemotherapeutic agent used for the treatment of colorectal liver metastasis; however, liver injury caused by oxaliplatin increases the risk of peri‑operative morbidity and mortality. Magnesium isoglycyrrhizinate (MgiG) is a magnesium salt of 18‑α glycyrrhizic acid stereoisomer that has demonstrated liver‑protective effects against toxins and hepatitis. In the present study, the liver‑protective effect of MgiG against oxaliplatin‑induced hepatic injury was examined in vitro and in vivo. The results demonstrated that MgiG had a protective effect against oxaliplatin‑induced liver injury, as evidenced by the alleviation of hepatic pathological damage and transaminase levels. The protective effect of MgiG was demonstrated to be correlated with inhibition of oxidative stress, the interleukin‑6 pathway and the coagulation system. Altogether, the present findings suggested that MgiG may have potential value in the clinical prevention and treatment of oxaliplatin‑induced liver injury.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, et al: Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial. Lancet. 377:2103–2114. 2011. View Article : Google Scholar : PubMed/NCBI
3	Beppu T, Sakamoto Y, Hayashi H and Baba H: Perioperative chemotherapy and hepatic resection for resectable colorectal liver metastases. Hepatobiliary Surg Nutr. 4:72–75. 2015.PubMed/NCBI
4	André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 350:2343–2351. 2004. View Article : Google Scholar : PubMed/NCBI
5	André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F and de Gramont A: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 27:3109–3116. 2009. View Article : Google Scholar : PubMed/NCBI
6	Portier G, Elias D, Bouche O, Rougier P, Bosset JF, Saric J, Belghiti J, Piedbois P, Guimbaud R, Nordlinger B, et al: Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol. 24:4976–4982. 2006. View Article : Google Scholar : PubMed/NCBI
7	Rubbia-Brandt L, Lauwers GY, Wang H, Majno PE, Tanabe K, Zhu AX, Brezault C, Soubrane O, Abdalla EK, Vauthey JN, et al: Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology. 56:430–439. 2010. View Article : Google Scholar : PubMed/NCBI
8	Slade JH, Alattar ML, Fogelman DR, Overman MJ, Agarwal A, Maru DM, Coulson RL, Charnsangavej C, Vauthey JN, Wolff RA and Kopetz S: Portal hypertension associated with oxaliplatin administration: Clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer. 8:225–230. 2009. View Article : Google Scholar : PubMed/NCBI
9	Hubert C, Fervaille C, Sempoux C, Horsmans Y, Humblet Y, Machiels JP, Zech F, Ceratti A and Gigot JF: Prevalence and clinical relevance of pathological hepatic changes occurring after neoadjuvant chemotherapy for colorectal liver metastases. Surgery. 147:185–194. 2010. View Article : Google Scholar : PubMed/NCBI
10	Robinson SM, Wilson CH, Burt AD, Manas DM and White SA: Chemotherapy-associated liver injury in patients with colorectal liver metastases: A systematic review and meta-analysis. Ann Surg Oncol. 19:4287–4299. 2012. View Article : Google Scholar : PubMed/NCBI
11	Rubbia-Brandt L, Tauzin S, Brezault C, Delucinge-Vivier C, Descombes P, Dousset B, Majno PE, Mentha G and Terris B: Gene expression profiling provides insights into pathways of oxaliplatin-related sinusoidal obstruction syndrome in humans. Mol Cancer Ther. 10:687–696. 2011. View Article : Google Scholar : PubMed/NCBI
12	Agostini J, Benoist S, Seman M, Julié C, Imbeaud S, Letourneur F, Cagnard N, Rougier P, Brouquet A, Zucman-Rossi J and Laurent-Puig P: Identification of molecular pathways involved in oxaliplatin-associated sinusoidal dilatation. J Hepatol. 56:869–876. 2012. View Article : Google Scholar
13	Sun L, Shen J, Pang X, Lu L, Mao Y and Zeng M: Phase I safety and pharmacokinetic study of magnesium isoglycyrrhizinate after single and multiple intravenous doses in chinese healthy volunteers. J Clin Pharmacol. 47:767–773. 2007. View Article : Google Scholar : PubMed/NCBI
14	Xu Q, Wang J, Chen F, Lin K, Zhu M, Chen L, Zhou X, Li C and Zhu H: Protective role of magnesium isoglycyrrhizinate in non-alcoholic fatty liver disease and the associated molecular mechanisms. Int J Mol Med. 38:275–282. 2016. View Article : Google Scholar : PubMed/NCBI
15	Cheng Y, Zhang J, Shang J and Zhang L: Prevention of free fatty acid-induced hepatic lipotoxicity in HepG2 cells by magnesium isoglycyrrhizinate in vitro. Pharmacology. 84:183–190. 2009. View Article : Google Scholar : PubMed/NCBI
16	Zhao HJ, Xiao L, Glizila B, Zhang H, Mao R, Xiong Y, Xu L, Shu MY, Bai YW and Bao YX: The effect and comparison of commonly used liver-protection drugs for irradiated HL-7702 by X. Zhonghua Gan Zang Bing Za Zhi. 25:612–617. 2017.In Chinese. PubMed/NCBI
17	Wang Y, Zhang Z, Wang X, Qi D, Qu A and Wang G: Amelioration of ethanol-induced hepatitis by magnesium isoglycyrrhizinate through inhibition of neutrophil cell infiltration and oxidative damage. Mediators Inflamm. 2017:35269032017. View Article : Google Scholar : PubMed/NCBI
18	Jiang W, Liu J, Li P, Lu Q, Pei X, Sun Y, Wang G and Hao K: Magnesium isoglycyrrhizinate shows hepatoprotective effects in a cyclophosphamide-induced model of hepatic injury. Oncotarget. 8:33252–33264. 2017.PubMed/NCBI
19	Lin Y, Li Y, Hu X, Liu Z, Chen J, Lu Y, Liu J, Liao S, Zhang Y, Liang R, et al: The hepatoprotective role of reduced glutathione and its underlying mechanism in oxaliplatin-induced acute liver injury. Oncol Lett. 15:2266–2272. 2018.PubMed/NCBI
20	He Y, Zeng F, Liu Q, Ju W, Fu H, Hao H, Li L and Xie Y: Protective effect of magnesium isoglycyrrhizinate on ethanol-induced testicular injuries in mice. J Biomed Res. 24:153–160. 2010. View Article : Google Scholar : PubMed/NCBI
21	Robinson SM, Mann J, Vasilaki A, Mathers J, Burt AD, Oakley F, White SA and Mann DA: Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model. J Hepatol. 59:318–326. 2013. View Article : Google Scholar : PubMed/NCBI
22	Xiong W, Ren ZG, Qiu SJ, Sun HC, Wang L, Liu BB, Li QS, Zhang W, Zhu XD, Liu L, et al: Residual hepatocellular carcinoma after oxaliplatin treatment has increased metastatic potential in a nude mouse model and is attenuated by Songyou Yin. BMC Cancer. 10:2192010. View Article : Google Scholar : PubMed/NCBI
23	Kelley MR, Jiang Y, Guo C, Reed A, Meng H and Vasko MR: Role of the DNA base excision repair protein, APE1 in cisplatin, oxaliplatin, or carboplatin induced sensory neuropathy. PLoS One. 9:e1064852014. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
25	Kweekel DM, Gelderblom H and Guchelaar HJ: Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev. 31:90–105. 2005. View Article : Google Scholar : PubMed/NCBI
26	McWhirter D, Kitteringham N, Jones RP, Malik H, Park K and Palmer D: Chemotherapy induced hepatotoxicity in metastatic colorectal cancer: A review of mechanisms and outcomes. Crit Rev Oncol Hematol. 88:404–415. 2013. View Article : Google Scholar : PubMed/NCBI
27	Hua W, Huang HZ, Tan LT, Wan JM, Gui HB, Zhao L, Ruan XZ, Chen XM and Du XG: CD36 mediated fatty acid-induced podocyte apoptosis via oxidative stress. PLoS One. 10:e01275072015. View Article : Google Scholar : PubMed/NCBI
28	Zhang S, Li X, Jourd'heuil FL, Qu S, Devejian N, Bennett E, Jourd'heuil D and Cai C: Cytoglobin promotes cardiac progenitor cell survival against oxidative stress via the upregulation of the NFκB/iNOS signal pathway and nitric oxide production. Sci Rep. 7:107542017. View Article : Google Scholar
29	Arafa E, Bondzie PA, Rezazadeh K, Meyer RD, Hartsough E, Henderson JM, Schwartz JH, Chitalia V and Rahimi N: TMIGD1 is a novel adhesion molecule that protects epithelial cells from oxidative cell injury. Am J Pathol. 185:2757–2767. 2015. View Article : Google Scholar : PubMed/NCBI
30	Madesh M and Hajnóczky G: VDAC-dependent permeabilization of the outer mitochondrial membrane by superoxide induces rapid and massive cytochrome c release. J Cell Biol. 155:1003–1015. 2001. View Article : Google Scholar : PubMed/NCBI
31	Lu Z, Cheng D, Yin J, Wu R, Zhang G, Zhao Q, Wang N, Wang F and Liang M: Antithrombin III protects against contrast-induced nephropathy. EBioMedicine. 17:101–107. 2017. View Article : Google Scholar : PubMed/NCBI
32	Gu X, Dong L, Liu Y and Yu F: Protective effect of magnesium isoglycyrrhizinate on acute hepatic injury induced by CCl4 in mice. China Pharmacist. 12:37–39. 2009.
33	DeLeve LD, McCuskey RS, Wang X, Hu L, McCuskey MK, Epstein RB and Kanel GC: Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology. 29:1779–1791. 1999. View Article : Google Scholar : PubMed/NCBI
34	Ma JQ, Ding J, Zhao H and Liu CM: Puerarin attenuates carbon tetrachloride-induced liver oxidative stress and hyperlipidaemia in mouse by JNK/c-Jun/CYP7A1 pathway. Basic Clin Pharmacol Toxicol. 115:389–395. 2014. View Article : Google Scholar : PubMed/NCBI
35	Nakamura K, Hatano E, Miyagawa-Hayashino A, Okuno M, Koyama Y, Narita M, Seo S, Taura K and Uemoto S: Soluble thrombomodulin attenuates sinusoidal obstruction syndrome in rat through suppression of high mobility group box 1. Liver Int. 34:1473–1487. 2014. View Article : Google Scholar : PubMed/NCBI
36	Schultze AE and Roth RA: Chronic pulmonary hypertension-the monocrotaline model and involvement of the hemostatic system. J Toxicol Environ Health B Crit Rev. 1:271–346. 1998. View Article : Google Scholar : PubMed/NCBI
37	Hassan MH, Bahashawan SA, Abdelghany TM, Abd-Allah GM and Ghobara MM: Crocin abrogates carbon tetrachloride-induced renal toxicity in rats via modulation of metabolizing enzymes and diminution of oxidative stress, apoptosis, and inflammatory cytokines. J Biochem Mol Toxicol. 29:330–339. 2015. View Article : Google Scholar : PubMed/NCBI
38	Bray TM and Taylor CG: Tissue glutathione, nutrition, and oxidative stress. Can J Physiol Pharmacol. 71:746–751. 1993. View Article : Google Scholar : PubMed/NCBI
39	Lu SC: Regulation of hepatic glutathione synthesis: Current concepts and controversies. FASEB J. 13:1169–1183. 1999. View Article : Google Scholar : PubMed/NCBI
40	Mulcahy RT, Bailey HH and Gipp JJ: Up-regulation of gamma-glutamylcysteine synthetase activity in melphalan-resistant human multiple myeloma cells expressing increased glutathione levels. Cancer Chemother Pharmacol. 34:67–71. 1994. View Article : Google Scholar : PubMed/NCBI
41	Li FY, Xie H, Weng L, Wang H, Cao LJ, Hao HP and Wang GJ: Effects of diammonium glycyrrhizinate on hepatic and intestinal UDP-Glucuronosyltransferases in rats: Implication in herb-drug interactions. Chin J Nat Med. 14:534–540. 2016.PubMed/NCBI
42	Liu M, Xu H, Zhang L, Zhang C, Yang L, Ma E, Liu L and Li Y: Salvianolic acid B inhibits myofibroblast transdifferentiation in experimental pulmonary fibrosis via the up-regulation of Nrf2. Biochem Biophys Res Commun. 495:325–331. 2018. View Article : Google Scholar
43	Wu R, Liu X, Yin J, Wu H, Cai X, Wang N, Qian Y and Wang F: IL-6 receptor blockade ameliorates diabetic nephropathy via inhibiting inflammasome in mice. Metabolism. 83:18–24. 2018. View Article : Google Scholar : PubMed/NCBI
44	Brouquet A, Benoist S, Julie C, Penna C, Beauchet A, Rougier P and Nordlinger B: Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases. Surgery. 145:362–371. 2009. View Article : Google Scholar : PubMed/NCBI
45	Angleton P, Chandler WL and Schmer G: Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation. 79:101–106. 1989. View Article : Google Scholar : PubMed/NCBI
46	Maiello M, Boeri D, Podesta F, Cagliero E, Vichi M, Odetti P, Adezati L and Lorenzi M: Increased expression of tissue plas-minogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose. Diabetes. 41:1009–1015. 1992. View Article : Google Scholar : PubMed/NCBI
47	Cagliero E, Roth T, Roy S, Maiello M and Lorenzi M: Expression of genes related to the extracellular matrix in human endothelial cells. Differential modulation by elevated glucose concentrations, phorbol esters, and cAMP. J Biol Chem. 266:14244–14250. 1991.PubMed/NCBI
48	Nordt TK, Schneider DJ and Sobel BE: Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease. Circulation. 89:321–330. 1994. View Article : Google Scholar : PubMed/NCBI
49	Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ and Collen D: Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemost. 60:491–494. 1988. View Article : Google Scholar : PubMed/NCBI
50	Lijnen HR: Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemostasis. 3:35–45. 2005. View Article : Google Scholar
51	Kooistr T: The use of cultured human endothelial cells and hepatocytes as an in vitro model system to study modulation of endogenous fibrinolysis = Fibrinolysis. 4(Suppl 2): S33–S39. 1990.